NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 388 filers reported holding NEKTAR THERAPEUTICS in Q3 2018. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $270,000 | -80.0% | 50,000 | -50.0% | 0.00% | -71.4% |
| Q4 2021 | $1,353,000 | -18.5% | 100,100 | +8.2% | 0.01% | -39.1% |
| Q3 2021 | $1,661,000 | -12.0% | 92,500 | -15.9% | 0.02% | 0.0% |
| Q2 2021 | $1,888,000 | +25.9% | 110,000 | +46.7% | 0.02% | +27.8% |
| Q1 2021 | $1,500,000 | -44.9% | 75,000 | -53.1% | 0.02% | +20.0% |
| Q4 2020 | $2,720,000 | +31.1% | 160,000 | +28.0% | 0.02% | -51.6% |
| Q3 2020 | $2,074,000 | -24.3% | 125,000 | +5.6% | 0.03% | -35.4% |
| Q2 2020 | $2,740,000 | +18.1% | 118,317 | -9.0% | 0.05% | -17.2% |
| Q1 2020 | $2,321,000 | -17.3% | 130,000 | 0.0% | 0.06% | -7.9% |
| Q4 2019 | $2,806,000 | +208.0% | 130,000 | +160.0% | 0.06% | +152.0% |
| Q3 2019 | $911,000 | -81.7% | 50,000 | -64.3% | 0.02% | -78.1% |
| Q2 2019 | $4,981,000 | -1.2% | 140,000 | -6.7% | 0.11% | +75.4% |
| Q1 2019 | $5,040,000 | +588.5% | 150,000 | +900.0% | 0.06% | +550.0% |
| Q2 2018 | $732,000 | – | 15,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |